JP2015517466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517466A5 JP2015517466A5 JP2015510380A JP2015510380A JP2015517466A5 JP 2015517466 A5 JP2015517466 A5 JP 2015517466A5 JP 2015510380 A JP2015510380 A JP 2015510380A JP 2015510380 A JP2015510380 A JP 2015510380A JP 2015517466 A5 JP2015517466 A5 JP 2015517466A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- composition
- kras
- strand
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 108091030071 RNAI Proteins 0.000 claims 20
- 230000009368 gene silencing by RNA Effects 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 19
- 102100030708 GTPase KRas Human genes 0.000 claims 15
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 15
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 230000000692 anti-sense effect Effects 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108091081021 Sense strand Proteins 0.000 claims 4
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- -1 salsasapogenin Chemical compound 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 claims 2
- 229920002101 Chitin Polymers 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 claims 2
- 229920001202 Inulin Polymers 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 2
- 206010029748 Noonan syndrome Diseases 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 229920001218 Pullulan Polymers 0.000 claims 2
- 239000004373 Pullulan Substances 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003431 cross linking reagent Substances 0.000 claims 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 claims 2
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 claims 2
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 2
- 229940029339 inulin Drugs 0.000 claims 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 150000002634 lipophilic molecules Chemical class 0.000 claims 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920005615 natural polymer Polymers 0.000 claims 2
- 229920000768 polyamine Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 235000019423 pullulan Nutrition 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 125000006853 reporter group Chemical group 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- 235000007586 terpenes Nutrition 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 150000003648 triterpenes Chemical class 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641588P | 2012-05-02 | 2012-05-02 | |
| US61/641,588 | 2012-05-02 | ||
| PCT/US2013/038847 WO2013166004A2 (en) | 2012-05-02 | 2013-04-30 | Organic compositions to treat kras-related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517466A JP2015517466A (ja) | 2015-06-22 |
| JP2015517466A5 true JP2015517466A5 (cg-RX-API-DMAC7.html) | 2016-06-23 |
Family
ID=48366565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510380A Pending JP2015517466A (ja) | 2012-05-02 | 2013-04-30 | Ｋｒａｓ関連疾患を処置するための有機組成物 |
Country Status (12)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620525A (zh) * | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
| CN106687121A (zh) | 2014-05-14 | 2017-05-17 | 亚历克斯利维斯兹奇管理和控股有限公司 | 改善的聚乙烯亚胺聚乙二醇载体 |
| US11180759B2 (en) * | 2016-01-19 | 2021-11-23 | The University Of North Carolina At Chapel Hill | Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| MA45470A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques kras et leurs utilisations |
| KR102543645B1 (ko) * | 2016-07-20 | 2023-06-16 | 주식회사 지씨지놈 | 유전성 발달장애 진단용 조성물 및 이의 용도 |
| IL319835A (en) | 2017-12-06 | 2025-05-01 | Avidity Biosciences Inc | Compositions and methods for treating muscular dystrophy and myotonic dystrophy |
| AU2020287343A1 (en) * | 2019-06-05 | 2021-12-09 | Southern Research Institute | Thiarabine- and thiarabine prodrug-based treatments |
| US12146139B2 (en) * | 2019-11-14 | 2024-11-19 | The Board Of Regents Of The University Of Oklahoma | Oligonucleotide interference treatments of prostate cancer |
| KR20220156867A (ko) | 2020-03-19 | 2022-11-28 | 어비디티 바이오사이언시스 인크. | 안면견갑상완 근이영양증의 치료용 조성물 및 방법 |
| JP2023521383A (ja) * | 2020-04-07 | 2023-05-24 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物 |
| EP4395901A4 (en) * | 2021-09-02 | 2025-10-01 | Molecular Axiom Llc | COMPOSITIONS AND METHODS FOR MODULATING KRAS EXPRESSION |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| EP4652279A2 (en) * | 2023-01-18 | 2025-11-26 | Molecular Axiom, LLC | Compositions for modulating kras expression and uses thereof |
| AU2024225428A1 (en) * | 2023-02-22 | 2025-08-28 | Altamira Therapeutics Ag | Compositions and methods for kras inhibition for the treatment of disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL151781A0 (en) | 2000-03-16 | 2003-04-10 | Genetica Inc | Methods and compositions for rna interference |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| ATE468861T1 (de) | 2001-08-16 | 2010-06-15 | Univ Pennsylvania | Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung |
| ES2354607T3 (es) | 2002-06-28 | 2011-03-16 | Protiva Biotherapeutics Inc. | Procedimiento y aparato para producir liposomas. |
| CA2500468A1 (en) | 2002-09-28 | 2004-04-08 | Massachussets Institute Of Technology | Influenza therapeutic |
| US8090542B2 (en) * | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| EP1585756B1 (en) | 2002-11-26 | 2010-04-21 | University of Massachusetts | Delivery of sirnas |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| JP4951338B2 (ja) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉ｒｎａ |
| WO2005021749A1 (en) | 2003-08-28 | 2005-03-10 | Novartis Ag | Interfering rna duplex having blunt-ends and 3’-modifications |
| EP1675949A2 (en) * | 2003-10-23 | 2006-07-05 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1714970A1 (en) * | 2005-04-22 | 2006-10-25 | Universität des Saarlandes | Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |
| CA2628300C (en) | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
| EP2002004B1 (en) | 2006-03-23 | 2015-10-14 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering rna |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| EP2081949B1 (en) * | 2006-09-22 | 2014-12-10 | GE Healthcare Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
| EP2121925A2 (en) * | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
| NZ580712A (en) | 2007-05-22 | 2011-12-22 | Marina Biotech Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers |
| EP2190995A2 (en) * | 2007-09-18 | 2010-06-02 | Intradigm Corporation | Compositions comprising k-ras sirna and methods of use |
| WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
| EP2238251B1 (en) | 2007-12-27 | 2015-02-11 | Protiva Biotherapeutics Inc. | Silencing of polo-like kinase expression using interfering rna |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| WO2010006237A2 (en) * | 2008-07-11 | 2010-01-14 | Alnylam Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents |
| WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
| EP3199165B1 (en) * | 2009-04-03 | 2022-06-08 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US20130116302A1 (en) * | 2010-03-12 | 2013-05-09 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Pharmaceutical composition for the treatment of chlamydial infection |
-
2013
- 2013-04-30 US US14/397,815 patent/US20150238515A1/en not_active Abandoned
- 2013-04-30 EP EP13721578.6A patent/EP2844757A2/en not_active Withdrawn
- 2013-04-30 AU AU2013256471A patent/AU2013256471A1/en not_active Abandoned
- 2013-04-30 CA CA3173610A patent/CA3173610A1/en active Pending
- 2013-04-30 CA CA2872304A patent/CA2872304C/en active Active
- 2013-04-30 BR BR112014027337A patent/BR112014027337A2/pt not_active IP Right Cessation
- 2013-04-30 EP EP17187348.2A patent/EP3272868A1/en not_active Ceased
- 2013-04-30 WO PCT/US2013/038847 patent/WO2013166004A2/en not_active Ceased
- 2013-04-30 EA EA201492004A patent/EA201492004A1/ru unknown
- 2013-04-30 CN CN201811456141.9A patent/CN109481455A/zh active Pending
- 2013-04-30 CN CN201380035099.2A patent/CN104583406A/zh active Pending
- 2013-04-30 HK HK15106884.9A patent/HK1206387A1/xx unknown
- 2013-04-30 JP JP2015510380A patent/JP2015517466A/ja active Pending
- 2013-04-30 MX MX2014013367A patent/MX2014013367A/es unknown
- 2013-04-30 EP EP20178501.1A patent/EP3736333A1/en active Pending
- 2013-04-30 KR KR20147033421A patent/KR20150004414A/ko not_active Withdrawn
-
2016
- 2016-07-11 AU AU2016204832A patent/AU2016204832A1/en not_active Abandoned
- 2016-09-07 US US15/258,042 patent/US20180153919A1/en not_active Abandoned
-
2017
- 2017-11-14 AU AU2017261481A patent/AU2017261481A1/en not_active Abandoned
-
2020
- 2020-01-14 AU AU2020200247A patent/AU2020200247A1/en not_active Abandoned
-
2022
- 2022-05-04 AU AU2022202991A patent/AU2022202991A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517466A5 (cg-RX-API-DMAC7.html) | ||
| JP2014525435A5 (cg-RX-API-DMAC7.html) | ||
| JP7728923B2 (ja) | 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート | |
| JP2015503608A5 (cg-RX-API-DMAC7.html) | ||
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| JP7160807B2 (ja) | 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート | |
| JP7118063B2 (ja) | 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート | |
| JP2016511256A5 (cg-RX-API-DMAC7.html) | ||
| JP2013525332A5 (cg-RX-API-DMAC7.html) | ||
| JP2013514321A5 (cg-RX-API-DMAC7.html) | ||
| JP2022528725A (ja) | 筋ジストロフィーを治療するための組成物 | |
| JP2018512060A5 (cg-RX-API-DMAC7.html) | ||
| US11261444B2 (en) | Organic compositions to treat EPAS1-related diseases | |
| JP2019504112A5 (cg-RX-API-DMAC7.html) | ||
| JP2018536689A5 (cg-RX-API-DMAC7.html) | ||
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| JP2014518612A5 (cg-RX-API-DMAC7.html) | ||
| US9080175B2 (en) | Organic compositions to treat Beta-ENaC-related diseases | |
| EP2765997A4 (en) | POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR | |
| NZ588583A (en) | Novel lipid formulations for nucleic acid delivery | |
| AR079494A1 (es) | Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1 | |
| JP2016513976A5 (cg-RX-API-DMAC7.html) | ||
| WO2019241385A2 (en) | Exon skipping oligomers for muscular dystropy | |
| JP2023539341A (ja) | Ｄｕｘ４阻害剤およびその使用方法 | |
| JP2019503199A5 (cg-RX-API-DMAC7.html) |